Praxis Precision Medicines Inc.
04/14/2026 | Press release | Distributed by Public on 04/14/2026 15:11
Material Event (Form 8-K)
Item 8.01. Other Events.
On April 14, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and Drug Administration (the "FDA") has accepted for review its New Drug Application for ulixacaltamide HCl for the treatment of essential tremor in adults. The FDA has set a target action date under the Prescription Drug User Fee Act of January 29, 2027 and is not planning to hold an advisory committee meeting.
Praxis Precision Medicines Inc. published this content on April 14, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 14, 2026 at 21:11 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]